1.83
Calcimedica Inc stock is traded at $1.83, with a volume of 15,470.
It is down -1.08% in the last 24 hours and down -16.82% over the past month.
See More
Previous Close:
$1.85
Open:
$1.85
24h Volume:
15,470
Relative Volume:
0.42
Market Cap:
$24.67M
Revenue:
-
Net Income/Loss:
$-13.59M
P/E Ratio:
-1.6944
EPS:
-1.08
Net Cash Flow:
$-19.79M
1W Performance:
-11.59%
1M Performance:
-16.82%
6M Performance:
-58.22%
1Y Performance:
-56.27%
Calcimedica Inc Stock (CALC) Company Profile
Name
Calcimedica Inc
Sector
Industry
Phone
858-952-5500
Address
505 COAST BOULEVARD SOUTH, LA JOLLA
Compare CALC with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CALC
Calcimedica Inc
|
1.83 | 24.67M | 0 | -13.59M | -19.79M | -1.08 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Calcimedica Inc Stock (CALC) Latest News
Analysts Offer Predictions for CalciMedica Q4 Earnings - Defense World
CalciMedica Inc. (CALC) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Corient Private Wealth LLC Buys New Shares in CalciMedica, Inc. (NASDAQ:CALC) - Defense World
CalciMedica (NASDAQ:CALC) Receives “Buy” Rating from HC Wainwright - Defense World
Graybug Vision stock hits 52-week low at $1.81 - Investing.com India
Graybug Vision stock hits 52-week low at $1.81 By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $16 target on CalciMedica stock - Investing.com India
CalciMedica Unveils Next-Gen Inflammatory Disease Treatments at Major Healthcare Conference - Stock Titan
CALCIMEDICA Earnings Results: $CALC Reports Quarterly Earnings - Nasdaq
CalciMedica Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Calcimedica Reports 2024 Financial Results And Provides Clinical & Corporate Updates - MarketScreener
CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates - PR Newswire
CalciMedica Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Atria Investments Inc Buys 7,509 Shares of CalciMedica, Inc. (NASDAQ:CALC) - Defense World
CalciMedica (CALC) Expected to Announce Quarterly Earnings on Thursday - Defense World
Graybug Vision stock hits 52-week low at $1.83 amid challenges - Investing.com
Head to Head Survey: Rani Therapeutics (NASDAQ:RANI) vs. CalciMedica (NASDAQ:CALC) - The AM Reporter
Rani Therapeutics (NASDAQ:RANI) versus CalciMedica (NASDAQ:CALC) Financial Contrast - Defense World
Promising Phase 2 Results and Market Potential Drive Buy Rating for CalciMedica’s Auxora - TipRanks
Short Interest in CalciMedica, Inc. (NASDAQ:CALC) Increases By 35.0% - Defense World
Latham & Watkins Advises CalciMedica in Secured Growth Financing - Latham & Watkins LLP
CalciMedica secures $32.5 million credit facility By Investing.com - Investing.com Canada
CalciMedica secures credit facility for up to $32.5M - MSN
CalciMedica Secures Credit Facility For Up To $32.5 Million -March 05, 2025 at 07:44 am EST - Marketscreener.com
CalciMedica secures $32.5 million credit facility - Investing.com India
CalciMedica Secures Credit Facility for Up to $32.5 Million - Finansavisen
CalciMedica (NASDAQ:CALC) Given “Buy” Rating at HC Wainwright - Defense World
Graybug Vision stock hits 52-week low at $1.95 amid challenges - Investing.com
CalciMedica reports reduced mortality in AKI trial with Auxora - Investing.com
CalciMedica Highlights Auxora’s Potential in COVID-19 Treatment - TipRanks
CalciMedica reports reduced mortality in AKI trial with Auxora By Investing.com - Investing.com South Africa
CalciMedica’s Auxora shows mortality reduction in COVID-19 pneumonia trial - TipRanks
CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference - PR Newswire
CalciMedica, Inc. (CALC): Among Penny Stocks with Insider Buying in 2025 - Insider Monkey
12 Penny Stocks with Insider Buying in 2025 - Insider Monkey
CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference - PR Newswire
CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Longview News-Journal
CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors - Victoria Advocate
CalciMedica announces board changes By Investing.com - Investing.com Australia
CalciMedica appoints new director amid clinical trials By Investing.com - Investing.com Nigeria
CalciMedica announces board changes - Investing.com
CalciMedica appoints new director amid clinical trials - Investing.com
CalciMedica Announces Board Changes and New Appointment - TipRanks
CalciMedica, Inc. (NASDAQ:CALC) Shares Acquired by Geode Capital Management LLC - Defense World
CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) - The Eastern Progress Online
CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting - The Eastern Progress Online
CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Eastern Progress Online
CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference - The Eastern Progress Online
Graybug Vision stock hits 52-week low at $2.65 amid market challenges - Investing.com Canada
CalciMedica Announces Presentations at Upcoming Medical Meetings - The Eastern Progress Online
CalciMedica director Fred Middleton buys $12,720 in stock By Investing.com - Investing.com Canada
Calcimedica Inc Stock (CALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):